The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 28, 2011

Filed:

Jul. 31, 2006
Applicants:

Antonio Giordani, Pavia, IT;

Stefano Mandelli, Casatenovo, IT;

Simona Zanzola, Milan, IT;

Francesca Tarchino, Varazze, IT;

Gianfranco Caselli, Milan, IT;

Teresa Simonetta Fiorentino, Monza, IT;

Silvio Mazzari, Padua, IT;

Francesco Makovec, Lesmo, IT;

Lucio Claudio Rovati, Monza, IT;

Inventors:

Antonio Giordani, Pavia, IT;

Stefano Mandelli, Casatenovo, IT;

Simona Zanzola, Milan, IT;

Francesca Tarchino, Varazze, IT;

Gianfranco Caselli, Milan, IT;

Teresa Simonetta Fiorentino, Monza, IT;

Silvio Mazzari, Padua, IT;

Francesco Makovec, Lesmo, IT;

Lucio Claudio Rovati, Monza, IT;

Assignee:

Rottapharm S.p.A., Milan, IT;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/517 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention concerns novel amidines derivatives of 2-heteroaryl-quinazoline and quinolines of general formula (I), to a process for their preparation, to their pharmaceutical compositions and to the use of these compounds, salts and solvates thereof, along with the corresponding pharmaceutical compositions, for the treatment of pain and inflammatory disorders. Compounds of this invention are extremely potent analgesics, suitable for the treatment of both inflammatory and neuropathic pain. Particularly for the treatment of neuropathic pain the compounds of the invention have been proved largely superior to the standards currently in the clinical use. These compounds are not acting through inhibition of COX or NOS enzymes but are effective in inhibiting inflammatory cytokine production induced by inflammatory stimuli.


Find Patent Forward Citations

Loading…